HALO vs LLY: fair value comparison
Halozyme Therapeutics, Inc. and Eli Lilly and Company · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LLY currently sits closer to the top of our discount ranking. HALO carries the stronger quality grade. HALO carries the stronger momentum grade.
| HALO | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $82.27 | $1,174.61 |
| 12-month range | $63.96–$82.27 | $735.19–$1,148.84 |
| Sector rank | #14 of 113 Healthcare | #12 of 113 Healthcare |
| Quality grade | A | D |
| Momentum grade | A | B |
| Leverage | High | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | High |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Fairly Valued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: HALO fair value analysis · LLY fair value analysis